Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phleum pratense pollen allergens, commonly known as Timothy grass pollen allergens, are a group of proteins primarily from groups 1-13 (e.g., Phl p 1 as beta-expansin, Phl p 5 as 32 kDa protein, Phl p 6 as 11 kDa group VI allergen) that elicit IgE-mediated immune responses in sensitized individuals. These allergens are major contributors to seasonal allergic rhinitis, asthma, and conjunctivitis in grass pollen-allergic patients, with Phl p 1 and Phl p 5 recognized by over 90% and 65% of patients, respectively, serving as markers of genuine sensitization. They trigger histamine release and inflammation upon inhalation, with isoforms showing structural variability (e.g., Phl p 5a at 38 kDa and Phl p 5b at 32 kDa) that influence epitope recognition and individual reactivity patterns. While not traditional therapeutic targets like receptors or enzymes, they are central to allergen immunotherapy (AIT), where recombinant forms or extracts desensitize patients by modulating IgE responses. Safety challenges include risk of systemic reactions during treatment, particularly in polysensitized individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phleum pratense pollen allergens (Phl p allergens).